Author:
Chen Chun-Yu,Pan Sheng-Wei,Hsu Chia-Chen,Liu Jason J.,Kumamaru Hiraku,Dong Yaa-Hui
Abstract
Abstract
Background
Use of combinations of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk associated with LABA/LAMA versus another dual combination, LABA/inhaled corticosteroids (ICS), was limited and discrepant.
Aim
The present cohort study aimed to examine comparative cardiovascular safety of LABA/LAMA and LABA/ICS with a target trial emulation framework, focusing on dual fixed-dose combination (FDC) therapies.
Methods
We identified patients with COPD who initiated LABA/LAMA FDC or LABA/ICS FDC from a nationwide Taiwanese database during 2017–2020. The outcome of interest was a hospitalized composite cardiovascular events of acute myocardial infarction, unstable angina, heart failure, cardiac dysrhythmia, and ischemic stroke. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for composite and individual cardiovascular events after matching up to five LABA/LAMA FDC initiators to one LABA/ICS FDC initiator using propensity scores (PS).
Results
Among 75,926 PS-matched patients, use of LABA/LAMA FDC did not show a higher cardiovascular risk compared to use of LABA/ICS FDC, with a HR of 0.89 (95% CI, 0.78–1.01) for the composite events, 0.80 (95% CI, 0.61–1.05) for acute myocardial infarction, 1.48 (95% CI, 0.68–3.25) for unstable angina, 1.00 (95% CI, 0.80–1.24) for congestive heart failure, 0.62 (95% CI, 0.37–1.05) for cardiac dysrhythmia, and 0.82 (95% CI, 0.66–1.02) for ischemic stroke. The results did not vary substantially in several pre-specified sensitivity and subgroup analyses.
Conclusion
Our findings provide important reassurance about comparative cardiovascular safety of LABA/LAMA FDC treatment among patients with COPD.
Funder
Yen Tjing Ling Medical Foundation
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. World Health Organization. Global health estimates: life expectancy and leading causes of death and disability 2019. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates Accessed 26 Feb 2023.
2. Taiwan Ministry of Health and Welfare. 2020 Cause of death statistics. https://www.mohw.gov.tw/lp-5256-2.html. Accessed 26 Feb 2023.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Diseases. 2023 Report. https://goldcopd.org/2023-gold-report-2/ Accessed 26 Feb 2023.
4. Billington CK, Penn RB, Hall IP. β2 agonists. Handb Exp Pharmacol. 2017;237:24–40.
5. Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb Exp Pharmacol. 2017;237:41–62.